TMCnet News

Orphazyme announces presentation of 2020 Annual Report
[February 23, 2021]

Orphazyme announces presentation of 2020 Annual Report

Orphazyme A/S
Investor news                                                                                                       

No. 03/2021                                                                                                           
Company Registration No. 32266355


Copenhagen, Denmark and Chicago, IL, USA, February 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases, today announced that the Company will be hosting an investor call during which the Orphazyme management team will be presenting the Company’s 2020 Annual Report. The presentation will be followed by a Q&A session.

The call will be held on Tuesday, March 2, 2021 at 2.00 PM CET.

Dial-in details:

  • Denmark: +45 32720417
  • France: +33 (0) 170700781
  • Netherlands: +31 (0) 207956614
  • Standard International: +44 (0) 2071 928338
  • Sweden: +46 (0) 856618467
  • United Kingdom: +44 (0) 8444819752
  • United States: +1 6467413167

Event Title: Orphazyme Annual Report 2020
Confirmation code: 8239516

The presentation will also be available via webcast:   

After the call, the presentation will be available via the above link.


For additional information, please contact
Orphazyme A/S

Anders Vadsholt, CFO                                  +45 28 98 90 55


About Orphazyme A/S 
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for?diseases caused by?protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular?degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA).?

About arimoclomol?
Arimoclomol is an investigational drug candidate that amplifies the production of Heat-Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, sIBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, IBM, and ALS in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC.  

Forward-looking statement 
This?company announcement?may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this?company announcement?about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by,?or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”,?and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance,?or achievements to be materially different from the expected results, performance,?or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.?? 



Primary Logo

[ Back To's Homepage ]